N/A
Manufactured by BM Private Limited
450 FDA adverse event reports analyzed
Last updated: 2026-04-15
MANGANESE SULFATE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by BM Private Limited. The most commonly reported adverse reactions for MANGANESE SULFATE include THROMBOCYTOPENIA, RESPIRATORY TRACT INFECTION, RESPIRATORY TRACT INFECTION VIRAL, COVID-19, RESPIRATORY TRACT INFECTION BACTERIAL. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for MANGANESE SULFATE.
Out of 78 classified reports for MANGANESE SULFATE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 450 FDA FAERS reports that mention MANGANESE SULFATE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include THROMBOCYTOPENIA, RESPIRATORY TRACT INFECTION, RESPIRATORY TRACT INFECTION VIRAL, COVID-19, RESPIRATORY TRACT INFECTION BACTERIAL, PULMONARY EMBOLISM. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list BM Private Limited in connection with MANGANESE SULFATE. Always verify the specific product and NDC with your pharmacist.